- Home
- ZDGE vs STTK Comparison
ZDGE vs STTK Comparison
Compare ZDGE & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- STTK
- Stock Information
- Founded
- ZDGE 2008
- STTK 2016
- Country
- ZDGE United States
- STTK United States
- Employees
- ZDGE N/A
- STTK N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ZDGE Technology
- STTK Health Care
- Exchange
- ZDGE Nasdaq
- STTK Nasdaq
- Market Cap
- ZDGE 50.5M
- STTK 59.7M
- IPO Year
- ZDGE N/A
- STTK 2020
- Fundamental
- Price
- ZDGE $2.76
- STTK $1.24
- Analyst Decision
- ZDGE
- STTK Hold
- Analyst Count
- ZDGE 0
- STTK 3
- Target Price
- ZDGE N/A
- STTK $2.00
- AVG Volume (30 Days)
- ZDGE 61.1K
- STTK 357.1K
- Earning Date
- ZDGE 12-11-2024
- STTK 11-14-2024
- Dividend Yield
- ZDGE N/A
- STTK N/A
- EPS Growth
- ZDGE N/A
- STTK N/A
- EPS
- ZDGE N/A
- STTK N/A
- Revenue
- ZDGE $30,091,000.00
- STTK $6,435,000.00
- Revenue This Year
- ZDGE $16.71
- STTK $115.09
- Revenue Next Year
- ZDGE $16.10
- STTK N/A
- P/E Ratio
- ZDGE N/A
- STTK N/A
- Revenue Growth
- ZDGE 10.46
- STTK 382.75
- 52 Week Low
- ZDGE $1.70
- STTK $1.07
- 52 Week High
- ZDGE $5.18
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- ZDGE 40.05
- STTK 38.29
- Support Level
- ZDGE $2.62
- STTK $1.14
- Resistance Level
- ZDGE $2.99
- STTK $1.56
- Average True Range (ATR)
- ZDGE 0.24
- STTK 0.12
- MACD
- ZDGE 0.00
- STTK 0.07
- Stochastic Oscillator
- ZDGE 26.14
- STTK 24.42
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.